Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

Design and Synthesis of Orally Bioavailable Aminopyrrolidinone Histone Deacetylase 6 Inhibitors

(2015) Xianfeng Lin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

(2015) S Kikuchi et al.   LEUKEMIA

Creation of a histone deacetylase 6 inhibitor and its biological effects

(2015) Ju-Hee Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

(2014) A. Garcia-Gomez et al.   CLINICAL CANCER RESEARCH

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors

(2013) T Hideshima et al.   LEUKEMIA

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

(2013) A Z Badros et al.   LEUKEMIA

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

(2013) H. A. F. Stessman et al.   MOLECULAR CANCER THERAPEUTICS

Sequence analysis of  -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

(2012) D. I. Lichter et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Stress management at the ER: Regulators of ER stress-induced apoptosis

(2012) Adrienne M. Gorman et al.   PHARMACOLOGY & THERAPEUTICS

Discovery of histone deacetylase 8 selective inhibitors

(2011) Weiping Tang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

(2010) Kyle V. Butler et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors

(2010) Floriana Morgillo et al.   LUNG CANCER

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

The art of the chemical probe

(2010) Stephen V Frye   Nature Chemical Biology

Biologic sequelae of I B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

(2009) T. Hideshima et al.   BLOOD

Impact of XIAP protein levels on the survival of myeloma cells

(2008) G. Desplanques et al.   HAEMATOLOGICA

Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors

(2008) Guillermina Estiu et al.   JOURNAL OF MEDICINAL CHEMISTRY